Pharmaceutical News

RSS

Lower socioeconomic status linked with inability to fight H1N1

People who did not earn a high school diploma could be more likely to get H1N1 and the vaccine might be less effective in them compared to those who earned a diploma, new research shows.

11 Nov 2009

Onyx Pharmaceuticals to present data on carfilzomib and ONX 0803 at the 51st ASH Annual Meeting

Onyx Pharmaceuticals, Inc. today announced nearly 20 presentations evaluating carfilzomib and ONX 0803 (SB 1518) in hematological cancers at the 51st American Society of Hematology (ASH) Annual Meeting December 5-8, 2009 in New Orleans, LA. Among the data presentations are four oral and seven poster presentations highlighting data from the carfilzomib development program in patients with relapsed and refractory multiple myeloma.

11 Nov 2009

Particle Sciences expands operations by acquiring new additional space

Particle Sciences Inc., a leading pharmaceutical CRO, has further expanded their capabilities by the acquisition of additional space bringing their total to approximately 21,000 sq ft.

11 Nov 2009

Allos Therapeutics awards NCCN a grant to evaluate pralatrexate

NCCN recently received a research grant from Allos Therapeutics, Inc. to evaluate the role of pralatrexate in the treatment of select hematologic malignancies and solid tumors. Pralatrexate is the only agent currently approved by the FDA to treat patients with relapsed or refractory peripheral T-cell lymphoma. Investigators from NCCN Member Institutions are eligible to apply for the research funding.

11 Nov 2009

New HPV vaccine eliminates chronic infection and reduces precancerous genital lesions in women

A new vaccine designed to stimulate an immune response against a cancer-causing human papillomavirus (HPV-16) can eliminate chronic infection by the virus and may cause regression of precancerous genital lesions in women who receive the vaccine.

11 Nov 2009

Mylan subsidiary receives FDA approval for its Lansoprazole DR Capsules ANDA

Mylan Inc. today announced that its privately held Indian subsidiary, Matrix Laboratories Limited, has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Lansoprazole Delayed-release (DR) Capsules, 15 mg and 30 mg. This product is shipping immediately and will be sold under the Mylan Pharmaceuticals brand.

11 Nov 2009

Sprycel holds hope for treating Src dependent ovarian cancer

The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found.

11 Nov 2009

Westaim executes amalgamation agreement with NUCRYST Pharmaceuticals

The Westaim Corporation today announced the execution of an amalgamation agreement with NUCRYST Pharmaceuticals Corp. (NASDAQ: NCST; TSX: NCS). Under the agreement, NUCRYST will amalgamate with a newly-formed, wholly-owned subsidiary of Westaim.

11 Nov 2009

Data on Alexion Pharmaceuticals' Soliris to be presented at the ASH meeting

Alexion Pharmaceuticals, Inc. today announced that researchers are scheduled to present data relating to Soliris® (eculizumab) as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) during the 51st Annual Meeting of the American Society of Hematology (ASH), to be held December 5 – 8, 2009 at the Ernst N. Morial Convention Center in New Orleans.

11 Nov 2009

Anemia-reducing medications linked to deep vein thrombosis in cancer patients

Medications frequently given to cancer patients to reduce their risk of anemia are associated with an increased risk of deep vein thrombosis or pulmonary embolism, according to new research led by Dawn Hershman, M.D, M.S., co-director of the breast cancer program at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital/Columbia University Medical Center. The findings will be published online on Nov. 10, 2009 in the Journal of the National Cancer Institute (ahead of the Dec. 2, 2009 print edition).

11 Nov 2009

Microbix Biosystems receives Health Canada's marketing and export approval for KINLYTIC

Microbix Biosystems Inc. today announced that KINLYTIC (urokinase for injection) has been approved in Canada for marketing and export. Health Canada's issuance of a Drug Identification Number for KINLYTIC gives Microbix the opportunity to market the product in Canada and export the clot-busting therapy to markets worldwide.

11 Nov 2009

Teva Pharmaceutical's generic lansoprazole does not infringe patent No. 5,464,632: U.S. Court

Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the District of Delaware has issued a decision in its litigation over the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Takeda Pharmaceuticals North America, Inc.'s Prevacid® (Lansoprazole) SoluTab.

10 Nov 2009

Cerimon Pharmaceuticals acquires rights to develop and commercialize diclofenac sodium patch in Europe

Cerimon Pharmaceuticals, Inc., announced today that it has acquired exclusive rights to develop and commercialize its once-daily topical diclofenac sodium patch in Europe, including most countries in the European Union, Turkey, Switzerland, Norway, the Balkan countries and Iceland. Terms of the agreement were not disclosed. Cerimon initially acquired the U.S. rights to develop and commercialize the patch formulation of diclofenac in 2005.

10 Nov 2009

U.S. DOD grant to study vigabatrin in combination with opiates to manage pain

Catalyst Pharmaceutical Partners, Inc. today reported that a team of neuroscientists at The Feinstein Institute for Medical Research at North Shore-Long Island Jewish Health System (LIJ) has received a $1.2 million grant from the U.S. Department of Defense (DOD) to conduct an animal study of the use of vigabatrin in combination with opiates to effectively manage pain while reducing the potential for opiate addiction.

10 Nov 2009

GSK to donate 50M H1N1 vaccine doses to WHO in coming months

Drugmaker GlaxoSmithKline announced plans on Tuesday to donate 50 million doses of its H1N1 (swine flu) vaccine to the WHO for use in developing countries within the next few months, Reuters reports. "We expect to start receiving [the first of the H1N1 doses] at the end of the month or early December and that the full 50 million will come by the end of spring," WHO spokesman Gregory Hartl said, adding, "We hope it is the first of many donations."

10 Nov 2009

Levulan PDT may reduce the rate of recurrence of SCCs in solid organ transplant recipients: Study

The results of an independent investigator study just published in the online version of Dermatologic Surgery demonstrate that Levulan(®) Photodynamic Therapy (PDT) may reduce the rate of recurrence of squamous cell carcinomas (SCCs) in solid organ transplant recipients (SOTRs), a population with a high incidence of nonmelanoma skin cancer.

10 Nov 2009

HHS Secretary to visit Bradenton Healthcare Center to discuss the importance of H1N1 vaccinations

Health and Human Services Secretary Kathleen Sebelius will visit the East Manatee Family Healthcare Center in Bradenton, Fla. on Tuesday, November 10.

10 Nov 2009

Despite economic slowdown, Central and Eastern European countries still represent an attractive healthcare market

Despite the global economic decline, Central and Eastern European (CEE) countries such as Poland, the Czech Republic, Slovakia, Hungary, Bulgaria and Romania still represent an attractive healthcare market.

10 Nov 2009

NIH awards $6.8 million subcontract to Kineta to develop vaccine immune boosters

Kineta, Inc. announced today it has been awarded a $6.8 million subcontract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop novel vaccine adjuvants (agents that help boost the immune system). The Kineta subcontract is part of a larger $13 million award to the University of Washington.

10 Nov 2009

Teva Pharmaceutical Industries amends patent infringement lawsuit against Momenta Pharmaceuticals/Sandoz

Teva Pharmaceutical Industries Ltd. announced today it is seeking to amend its existing complaint against Momenta Pharmaceuticals, Inc./Sandoz Inc. to include patent infringement of three additional patents related to the characterization of COPAXONE® (glatiramer acetate injection). The proposed updated complaint has been filed under seal with the U.S. District Court for the Southern District of New York along with a motion requesting that the Court grant Teva leave to amend.

10 Nov 2009

Pharmaceutical News

Lower socioeconomic status linked with inability to fight H1N1

Onyx Pharmaceuticals to present data on carfilzomib and ONX 0803 at the 51st ASH Annual Meeting

Particle Sciences expands operations by acquiring new additional space

Allos Therapeutics awards NCCN a grant to evaluate pralatrexate

New HPV vaccine eliminates chronic infection and reduces precancerous genital lesions in women

Mylan subsidiary receives FDA approval for its Lansoprazole DR Capsules ANDA

Sprycel holds hope for treating Src dependent ovarian cancer

Westaim executes amalgamation agreement with NUCRYST Pharmaceuticals

Data on Alexion Pharmaceuticals' Soliris to be presented at the ASH meeting

Anemia-reducing medications linked to deep vein thrombosis in cancer patients

Microbix Biosystems receives Health Canada's marketing and export approval for KINLYTIC

Teva Pharmaceutical's generic lansoprazole does not infringe patent No. 5,464,632: U.S. Court

Cerimon Pharmaceuticals acquires rights to develop and commercialize diclofenac sodium patch in Europe

U.S. DOD grant to study vigabatrin in combination with opiates to manage pain

GSK to donate 50M H1N1 vaccine doses to WHO in coming months

Levulan PDT may reduce the rate of recurrence of SCCs in solid organ transplant recipients: Study

HHS Secretary to visit Bradenton Healthcare Center to discuss the importance of H1N1 vaccinations

Despite economic slowdown, Central and Eastern European countries still represent an attractive healthcare market

NIH awards $6.8 million subcontract to Kineta to develop vaccine immune boosters

Teva Pharmaceutical Industries amends patent infringement lawsuit against Momenta Pharmaceuticals/Sandoz

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News